@article{99a8b7fa5b13474ab0ce19abc068a326,
title = "Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML",
author = "Hu Xie and Becker, \{Pamela S.\} and Pagel, \{John M.\} and Walter, \{Roland B.\} and Vicky Sandu and Hendrie, \{Paul C.\} and Janis Abkowtiz and Appelbaum, \{Frederick R.\} and Estey, \{Elihu H.\}",
note = "Introduction Mangement of AML typically calls for a bone marrow aspirate 7-10 days after completion of induction therapy with standard or high-dose cytarabine (HiDAC)-containing regimens (day 14 marrow). If this marrow contains 5-10\% blasts, National Comprehensive Cancer Network guidelines recommend a second course of induction therapy.",
year = "2013",
month = nov,
day = "15",
language = "American English",
volume = "122",
journal = "Blood",
}